As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Agenus Inc. The largest reported stake is Raymond Debbane's, at 9.99%. 8 filings are on record since July 16, 2025 (Schedule 13G, July 17, 2026).
Sell to companies like Agenus Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: BlackRock, Inc. · Sole voting: 2,485,590 · Shared voting: 0 · Sole dispositive: 2,513,893 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-27
- · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 4,344,772 · Sole dispositive: 0 · Shared dispositive: 4,344,772 · SCHEDULE 13G, 2026-07-20
- · Reporting person: Invus Public Equities, L.P. · Sole voting: 3,971,647 · Shared voting: 0 · Sole dispositive: 3,971,647 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-17
- · Reporting person: The Vanguard Group · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-03-26
- · Holder: Zynext Ventures Usa LLC · Percent: 5.9% · SCHEDULE 13D
Agenus Inc has 8 Schedule 13D or 13G filings on record since 2025-07-16. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 9.99% | 4,533,755 | SCHEDULE 13G, 2026-07-17 | 2026-07-13 | |
| RA Capital Management, L.P. | 9.9% | 4,344,772 | SCHEDULE 13G, 2026-07-20 | 2026-07-13 |
| BlackRock, Inc. | 6% | 2,513,893 | SCHEDULE 13G, 2026-07-27 | 2026-06-30 |
| Zynext Ventures Usa LLC | 5.9% | 2,133,333 | SCHEDULE 13D, 2026-01-23 | 2026-01-15 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind Agenus Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Agenus Inc and the records around it.
Agenus Inc elsewhere on the record
Companies that share a holder
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Agenus Inc
Get an email when Agenus Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Agenus Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Agenus Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Agenus Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 3,971,647 | 0 | 3,971,647 | 0 | SCHEDULE 13G, 2026-07-17 |
| Invus Public Equities Advisors, LLC | 3,971,647 | 0 | 3,971,647 | 0 | SCHEDULE 13G, 2026-07-17 |
| Invus Global Management, LLC | 3,971,647 | 0 | 3,971,647 | 0 | SCHEDULE 13G, 2026-07-17 |
| Siren, L.L.C. | 3,971,647 | 0 | 3,971,647 | 0 | SCHEDULE 13G, 2026-07-17 |
| Avicenna Life Sci Master Fund LP | 562,108 | 0 | 562,108 | 0 | SCHEDULE 13G, 2026-07-17 |
| Avicenna Life Sci Master GP LLC | 562,108 | 0 | 562,108 | 0 | SCHEDULE 13G, 2026-07-17 |
| Ulys, L.L.C. | 562,108 | 0 | 562,108 | 0 | SCHEDULE 13G, 2026-07-17 |
| Raymond Debbane | 4,533,755 | 0 | 4,533,755 | 0 | SCHEDULE 13G, 2026-07-17 |
| RA Capital Management, L.P. | 0 | 4,344,772 | 0 | 4,344,772 | SCHEDULE 13G, 2026-07-20 |
| Peter Kolchinsky | 0 | 4,344,772 | 0 | 4,344,772 | SCHEDULE 13G, 2026-07-20 |
| Rajeev Shah | 0 | 4,344,772 | 0 | 4,344,772 | SCHEDULE 13G, 2026-07-20 |
| RA Capital Healthcare Fund, L.P. | 0 | 4,344,772 | 0 | 4,344,772 | SCHEDULE 13G, 2026-07-20 |
| BlackRock, Inc. | 2,485,590 | 0 | 2,513,893 | 0 | SCHEDULE 13G, 2026-07-27 |
| The Vanguard Group | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-03-26 |
The latest filing identifies Agenus Inc by CUSIP 00847G804 and gives its principal executive office as 3 FORBES ROAD, LEXINGTON, MA 02421 (SCHEDULE 13G, 2026-07-27).
What the percentages are based on
As of July 13, 2026, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person's cover page.Raymond Debbane, SCHEDULE 13G, 2026-07-17
Due to the Beneficial Ownership Blockers listed in the Warrants, each Reporting Person's beneficial ownership percentage is 9.99%.RA Capital Management, L.P., SCHEDULE 13G, 2026-07-20
Purpose of Transaction (Item 4)
Zynext Ventures Usa LLC
The acquisition of securities of the issuer is part of a strategic collaboration between Zydus and the issuer. At Zydus?s option, Zydus may appoint either a board observer or board member to issuer?s board of directors so long as Zydus retains significant ownership of issuer?s stock.Item 4 of the SCHEDULE 13D filed 2026-01-23
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-16 | BlackRock, Inc. | 1.8% | SCHEDULE 13G/A |
| 2025-07-29 | The Vanguard Group | 9.23% | SCHEDULE 13G/A |
| 2025-10-30 | The Vanguard Group | 8.06% | SCHEDULE 13G/A |
| 2026-01-23 | Zynext Ventures Usa LLC | 5.9% | SCHEDULE 13D |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-07-17 | Raymond Debbane | 9.99% | SCHEDULE 13G |
| 2026-07-20 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G |
| 2026-07-27 | BlackRock, Inc. | 6% | SCHEDULE 13G |
Questions about who owns Agenus Inc
Who owns Agenus Inc?
On this page, 4 holders' latest ownership filings report 5% or more of Agenus Inc: Raymond Debbane (9.99%, Schedule 13G, filed 2026-07-17), RA Capital Management, L.P. (9.9%, Schedule 13G, filed 2026-07-20), BlackRock, Inc. (6%, Schedule 13G, filed 2026-07-27) and Zynext Ventures Usa LLC (5.9%, Schedule 13D, filed 2026-01-23).
Who are the largest shareholders of Agenus Inc?
By the share each holder's latest filing reports, the largest holders of Agenus Inc on this page are Raymond Debbane (9.99%), RA Capital Management, L.P. (9.9%) and BlackRock, Inc. (6%).
When did Raymond Debbane buy into Agenus Inc?
The filings give report dates, not purchase dates. The earliest filing from Raymond Debbane on this page is the Schedule 13G, filed 2026-07-17, reporting 9.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Agenus Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 11, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| May 15, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Agenus Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.